158 related articles for article (PubMed ID: 34796446)
21. Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer.
Jakubowska K; Naumnik W; Niklińska W; Chyczewska E
Adv Exp Med Biol; 2015; 852():49-58. PubMed ID: 25753556
[TBL] [Abstract][Full Text] [Related]
22. Comparison of tissue biomarkers between non-schistosoma and schistosoma-associated urothelial carcinoma.
AlHariry NS; El Saftawy EA; Aboulhoda BE; Abozamel AH; Alghamdi MA; Hamoud AE; Khalil Ghanam WAE
Tissue Cell; 2024 Jun; 88():102416. PubMed ID: 38796863
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients.
Li M; Cai Y; Zhao H; Xu Z; Sun Q; Luo M; Gu L; Meng M; Han X; Sun H
Tumour Biol; 2015 Jun; 36(6):4785-92. PubMed ID: 25647262
[TBL] [Abstract][Full Text] [Related]
24. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).
Richter P; Junker K; Franz M; Berndt A; Geyer C; Gajda M; Kosmehl H; Berndt A; Wunderlich H
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1059-65. PubMed ID: 18386055
[TBL] [Abstract][Full Text] [Related]
25. A novel diagnostic tool for the detection of bladder cancer: Measurement of urinary high mobility group box-1.
Benlier N; Solakhan M; Yıldırım Z; Kaya V; Yıldırım ÖA; Orhan N; Çiçek H; Yıldırım M
Urol Oncol; 2020 Aug; 38(8):685.e11-685.e16. PubMed ID: 32312640
[TBL] [Abstract][Full Text] [Related]
26. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder.
Zaravinos A; Volanis D; Lambrou GI; Delakas D; Spandidos DA
Oncol Rep; 2012 Oct; 28(4):1159-66. PubMed ID: 22895562
[TBL] [Abstract][Full Text] [Related]
27. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
[TBL] [Abstract][Full Text] [Related]
28. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
[TBL] [Abstract][Full Text] [Related]
29. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
[TBL] [Abstract][Full Text] [Related]
30. Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology.
Barak V; Itzkovich D; Einarsson R; Gofrit O; Pode D
Anticancer Res; 2020 Jul; 40(7):3967-3972. PubMed ID: 32620639
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer.
Warrick JI; Raman JD; Kaag M; Bruggeman T; Cates J; Clark P; DeGraff DJ
Urol Oncol; 2016 Jun; 34(6):258.e1-6. PubMed ID: 26976725
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
33. Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer.
Matuszewski M; Szymańska B; Długosz A; Małkiewicz B; Dembowski J; Piwowar A
Biomed Res Int; 2018; 2018():8693297. PubMed ID: 30627578
[TBL] [Abstract][Full Text] [Related]
34. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105
[TBL] [Abstract][Full Text] [Related]
35. Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer.
Agreda Castañeda F; Raventós Busquets CX; Morote Robles J
Clin Genitourin Cancer; 2020 Jun; 18(3):230-235. PubMed ID: 31911121
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
37. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.
Sheng X; Du X; Zhang X; Li D; Lu C; Li Q; Ma Z; Song Q; Wang C
Croat Med J; 2009 Oct; 50(5):455-64. PubMed ID: 19839069
[TBL] [Abstract][Full Text] [Related]
38. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma.
Svatek RS; Karam J; Karakiewicz PI; Gallina A; Casella R; Roehrborn CG; Shariat SF
J Urol; 2008 Feb; 179(2):478-84; discussion 484. PubMed ID: 18076936
[TBL] [Abstract][Full Text] [Related]
39. Beclin 1 and bcl-2 expressions in bladder urothelial tumors and their association with clinicopathological parameters.
Baspinar S; Bircan S; Yavuz G; Kapucuoglu N
Pathol Res Pract; 2013 Jul; 209(7):418-23. PubMed ID: 23722017
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a New Survivin ELISA and UBC
Gleichenhagen J; Arndt C; Casjens S; Meinig C; Gerullis H; Raiko I; Brüning T; Ecke T; Johnen G
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29324722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
